We focused on EpCAM-negative CTCs possessing alternative combinations of urokinase plasminogen activator receptor (uPAR) and integrin β1 (int β1), two biomarkers known to be directly implicated in breast cancer dormancy1, 2. This evidence concerns the gene PLAUR and breast cancer.